Confidence in “HiCardi” and “HiCardi Plus” amid the full-scale intensification of competition among tertiary hospitals this year

Nurturing the next-generation product “HiCardi M350” as a key lever to widen the technology gap in overseas markets

Park Jung-hwan, CEO of Mezoo, explains the HiCardi solution during an interview conducted at the company’s R&D center in Wonju, Gangwon Province. / Photo = Mezoo

“This year, when competition centered on tertiary hospitals intensifies in earnest, I am confident that Mezoo’s solutions—designed from the outset for large hospitals—will prove their competitiveness,” said Park Jung-hwan, CEO of Mezoo.

Mezoo, an ambulatory Remote Patient Monitoring (aRPM) company, is entering a phase of full-scale market competition following its IPO preparations. On the 20th, Mezoo filed its securities registration statement and initiated the public offering process for its KOSDAQ listing.

Mezoo’s strategy is to elevate its position in the aRPM market by demonstrating the competitiveness of solutions tailored to the needs of advanced hospitals, while accelerating next-generation product development and overseas market expansion. The company’s core focus is aRPM technology that enables continuous measurement and transmission of vital signs even in environments where patients are mobile rather than confined to beds. Its key products are the wearable patch-based “HiCardi” and “HiCardi Plus.” These solutions collect ECG-centered biometric signals in real time and transmit them to hospital servers or the cloud, allowing medical staff to monitor multiple patients simultaneously on a single screen. Leveraging these strengths, Mezoo achieved cumulative sales of KRW 5.3 billion as of the third quarter of last year, surpassing its total revenue for the previous year (KRW 2.4 billion) and demonstrating strong growth momentum.

source : https://www.mt.co.kr/thebio/2026/02/02/2026013014362892456